Achieving blood pressure targets and antihypertensive effects through metabolic surgery in type 2 diabetes patients with hypertension

Abstract

Short Summary This was a prospective study of 535 diabetes patients who underwent metabolic surgery (n = 112) and medical treatment (n = 423). Metabolic surgery decreased both office systolic blood pressure (SBP) and diastolic blood pressure (DBP) and also significantly reduced ambulatory SBP (132 ± 2 vs. 119 ± 1 mmHg, p < 0.0001). Moreover, the rate of achieving the target SBP of 130 and 140 mmHg was also significantly higher in the surgery group. The defined daily dose of antihypertensive medication was significantly decreased in after surgery. Furthermore, metabolic surgery markedly improved the risks of atherosclerotic cardiovascular disease. In conclusion, metabolic surgery can effectively achieve the BP target and improve multiple metabolic dysfunction in type 2 diabetes mellitus patients with hypertension.

Chitosan Nanoparticles in Atherosclerosis—Development to Preclinical Testing

“…Atherosclerosis is responsible for a majority of cardiovascular disease deaths [ 6 , 7 ]. Risk factors or triggers for the disease include high cholesterol, triglyceride and saturated fat levels (mainly through the diet), smoking, high blood pressure, obesity, and reduced or nil physical activity [ 8 , 9 , 10 ].…”